Theraclion

Equities

ALTHE

FR0010120402

Advanced Medical Equipment & Technology

Real-time Euronext Paris Other stock markets 03:04:22 2024-05-16 am EDT			5-day change	1st Jan Change
0.5 ^EUR	+1.21%		+12.27%	+27.32%

Mar. 27	Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study	CI

THERACLION Announces Sales Results for the First Half Ended June 30, 2019; Provides Revenue Guidance for the Second Half of 2019

July 22, 2019 at 02:00 pm EDT

THERACLION announced sales results for the first half ended June 30, 2019. For the period, the company reported total sales of EUR 963,000 compared to EUR 862,000 a year ago.

The company also provided revenue guidance for the second half of 2019. The company expected to accelerate its sales growth in second half of 2019 to reach between 30% and 50% sales growth this year.

Latest news about Theraclion

Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study	23-10-24	CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-11	CI
Inner Mongolia Furui Medical Science Co., Ltd. agreed to acquire an additional 27.78% stake in Theraclion Medical Equipment Co., Ltd. from Theraclion SA for ?1	23-09-27	CI
Theraclion: capital increase completed	23-06-23	CF
Theraclion SA announced that it has received â‚¬8.353961 million in funding from Furui Medical Science Company Luxembourg S.Ã r.l.	23-06-21	CI
Theraclion Names CEO	23-05-26	MT
Theraclion Appoints Martin Deterre as CEO	23-05-25	CI
Theraclion SA announced that it expects to receive €7 million in funding from Furui Medical Science Company Luxembourg S.à r.l.	23-05-24	CI
Theraclion SA announced that it expects to receive ?12.649999 million in funding from Furui Medical Science Company Luxembourg S.à r.l.	23-05-23	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	23-05-02
Theraclion SA Auditor Raises 'Going Concern' Doubt	23-04-28	CI
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Theraclion: FDA approves pivotal study with Sonovein	23-04-18	CF
France's Theraclion Gets US FDA Nod for Clinical Trial of Varicose Veins Treatment	23-04-18	MT
Theraclion SA Announces US Food Drug Administration Approve Investigational Device Exemption Application to Initiate the Multi-Center Pivotal Study VEINRESET for the Treatment of Primary Insufficiency of Great Saphenous Veins with SONOVEIN	23-04-17	CI
Theraclion: boosted by positive results from US study	23-01-31	CF
Theraclion Announces Results of First US Trial	23-01-30	CI
Theraclion: partnership with the University of Virginia	22-12-22	CF
University of Virginia Cancer Center to Use Theraclion's HD Technology	22-12-21	CI
Theraclion SA Announces Last Patient of First Sonovein(R) US Study Has Been Treated	22-10-17	CI
Theraclion New Echotherapy for Varicose Veins Partnership with Parisian Region Hospital Wound Center Announced	22-09-29	CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Theraclion SA Announces Revenue Result for the First Half of 2022	22-07-27	CI
Theraclion SA Announces the Launch of SONOVEIN® HD	22-05-16	CI

Chart Theraclion

Duration

Period

More charts

Company Profile

Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of equipment (66.1%); - sale of consumables (27.8%); - provision of after-sales services (6.1%). Export accounts for 96.6% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERACLION	+27.32%	24.34M
THERMO FISHER SCIENTIFIC	+12.85%	229B
DANAHER CORPORATION	+13.88%	195B
INTUITIVE SURGICAL, INC.	+18.39%	142B
BOSTON SCIENTIFIC CORPORATION	+28.78%	109B
SIEMENS HEALTHINEERS AG	+1.67%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+18.24%	54.33B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	52.09B
AGILENT TECHNOLOGIES, INC.	+10.83%	45.15B
GE HEALTHCARE TECHNOLOGIES INC.	+5.94%	37.39B

Other Advanced Medical Equipment & Technology